Mark Hoppus revealed on a Q&A livestream that he was diagnosed with the same form of cancer that his mother previously battled.

Monjuvi shows real-world effectiveness in relapsed/refractory DLBCL, with 11.3 months PFS and 24.8 months OS. Second-line Monjuvi treatment yields higher ORR (78.5%) compared to third-line (62.8%).

Circulating tumor DNA (ctDNA) minimal residual disease (MRD) assessment at treatment completion provides superior prognostic accuracy compared with PET in large B-cell lymphoma. The CLARITY assay ...

Roche Holding said a combination of Lunsumio and Polivy significantly prolonged remission for patients with relapsed or refractory large B-cell lymphoma in a late-stage trial. The Swiss pharmaceutical ...

Studies presented at the ASH Annual Meeting 2025 highlighted a novel prognostic approach and emerging treatment strategies in lymphoma.